Crohn-betegség: vizsgálatok itt: Ausztria
18 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 12.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleA clinical study of MK-7240 for the treatment of Crohn’s disease (MK-7240-008)
- Where
- Innsbruck, Salzburg, Vienna
- Életkor
- 18 év and over
- People
- 567 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to join2024-518296-56-00 - 3. fázisTaking peopleA Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
- Where
- Innsbruck, Salzburg, Vienna
- Életkor
- 16 év to 80 év
- People
- 1200 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06430801 · EU 2023-508636-61-00 - 2. fázisTaking peopleA Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
- Where
- Innsbruck, Salzburg, St. Poelten, Vienna
- Életkor
- 18 év to 85 év
- People
- 385 worldwide
- Run by
- Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)
See details and how to joinNCT06226883 · EU 2023-508158-24-00 - 3. fázisTaking peopleMirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
- Where
- Graz, Innsbruck, Vienna
- Életkor
- 18 év to 70 év
- People
- 290 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT06937099 · EU 2024-520210-21-00 - 3. fázisTaking peopleA Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
- Where
- Vienna
- Életkor
- 2 év to 17 év
- People
- 120 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT05923073 · EU 2023-504735-41-00 - 3. fázisTaking peopleA Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
- Where
- Graz, Innsbruck, Linz, Salzburg, Vienna, Wels, Wiener Neustadt
- Életkor
- 18 év and over
- People
- 530 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT07499232 - 3. fázisTaking peopleA Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
- Where
- Graz, Klagenfurt Am Woerthersee, Linz, Salzburg, St. Poelten, Vienna, Wels
- Életkor
- 18 év and over
- People
- 460 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT07577843 · EU 2026-525922-39-00 - No phaseTaking peopleA Study of Guselkumab in Participants With Crohn's Disease and Ulcerative Colitis
- Where
- Vienna
- Életkor
- 18 év and over
- People
- 35
- Run by
- Janssen-Cilag Pharma GmbH
See details and how to joinNCT07606339 - 3. fázisTaking peopleA Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
- Where
- Linz, Wels
- Életkor
- 16 év to 80 év
- People
- 425 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT06819891 · EU 2024-513054-30-00 - 3. fázisTaking peopleAn Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- Where
- Graz, Krems, Linz, Salzburg, Sankt Veit an der Glan, Vienna
- Életkor
- 16 év to 80 év
- People
- 980 worldwide
- Run by
- Sanofi
See details and how to joinNCT07184931 - 3. fázisTaking peopleA Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- Where
- Vienna
- Életkor
- 16 év to 80 év
- People
- 751 worldwide
- Run by
- Sanofi
See details and how to joinNCT07184944 - 3. fázisTaking peopleA Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
- Where
- Innsbruck, St. Poelten, Vienna
- Életkor
- 16 év to 80 év
- People
- 600 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT06819878 · EU 2024-513053-69-00 - 2. fázisTaking peopleA clinical trial to assess the efficacy and safety of ontunisertib compared to placebo in patients with fibrostenosing Crohn’s disease
- Where
- Graz, Klagenfurt Am Woerthersee, Linz, Salzburg, Tulln An Der Donau, Vienna
- Életkor
- 18 év and over
- People
- 160 worldwide
- Run by
- Agomab Spain S.L.U.
See details and how to join2026-525197-19-00 - 3. fázisTaking peopleA Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
- Where
- Vienna
- Életkor
- 2 év to 19 év
- People
- 150 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT04844606 - 3. fázisTaking peopleA Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
- Where
- Vienna
- Életkor
- 2 év to 17 év
- People
- 90 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT05509777 · EU 2024-511472-32-00 - 2. fázisTaking peopleStudy of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
- Where
- Graz, Innsbruck, Linz, Salzburg, Vienna, Wels
- Életkor
- 18 év to 75 év
- People
- 590 worldwide
- Run by
- AbbVie
See details and how to joinNCT06548542 · EU 2024-513009-30-00 - 3. fázisTaking peopleCrohn’s Head-to-Head Assessing Risankizumab Versus Guselkumab for One Year
- Where
- Graz, Innsbruck, Linz, Salzburg, Vienna, Wels, Wiener Neustadt
- Életkor
- 18 év and over
- People
- 302 worldwide
- Run by
- Janssen Cilag International
See details and how to join2025-521590-13-00 - 3. fázisTaking peopleA Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
- Where
- Innsbruck, Linz, Salzburg, Vienna
- Életkor
- 18 év to 65 év
- People
- 396 worldwide
- Run by
- Takeda
See details and how to joinNCT06227910 · EU 2023-509391-42-00